Investors and Media

Press Releases

May 31, 2018

Scholar Rock Announces Completion of Dosing of First Cohort in Phase 1 Clinical Trial of SRK-015

May 23, 2018

Scholar Rock Announces Pricing of Initial Public Offering

April 9, 2018

Scholar Rock Appoints Rhonda Chicko as Chief Financial Officer

March 29, 2018

Scholar Rock Granted Orphan Drug Designation by the FDA for SRK-015 for the Treatment of Patients with Spinal Muscular Atrophy

February 2, 2018

Scholar Rock Announces Publication of Comprehensive Pharmacological Study of SRK-015, a Novel Inhibitor of Myostatin Activation, Supporting the Treatment of Muscle Atrophy Disorders

January 23, 2018

Scholar Rock and Collaborators at Harvard Medical School and Northeastern University Elucidate Molecular Basis of Myostatin Activation – a Key Physiological Process in Muscle Health

January 3, 2018

Scholar Rock Announces $47 Million Series C Financing to Advance Innovative Pipeline for SMA, Immuno-Oncology, Fibrosis, and Iron-Restricted Anemias

September 14, 2017

Scholar Rock Announces Issuance of Broad Patent Covering Therapeutic Approach for Neuromuscular Diseases

Archived Press Releases